The GSK share price (LON: GSK) is currently trading at 2,076.00 GBX as of March 31, 2026, representing a steady upward trend following strong 2025 financial results. Investors are closely monitoring GSK as it reaffirms its 2026 guidance, targeting a turnover growth of 3% to 5% and core earnings per share (EPS) growth of 7% to 9%. The company’s focus on Specialty Medicines, HIV treatments, and high-growth vaccines like Shingrix and Arexvy has bolstered market confidence, with a projected total dividend of 70p per share for the full year 2026.
In this comprehensive guide, you will find a deep dive into GSK’s current market valuation, dividend schedules, and the pivotal clinical trials shaping its future. We analyze the impact of recent FDA approvals, the strategic acquisition of RAPT Therapeutics, and how the company aims to reach its ambitious 2031 sales target of over £40 billion. Whether you are looking for technical price levels or long-term fundamental analysis, this guide provides the authoritative data needed to navigate GSK’s performance in the global pharmaceutical sector.
Current GSK Market Performance
As of late March 2026, GSK plc maintains a robust market capitalization of approximately £112.5 billion. The stock has shown resilience, trading significantly above its 52-week low of 1,242.50 GBX, though it remains below the yearly high of 2,282.00 GBX.
The price-to-earnings (P/E) ratio currently sits near 14.9, suggesting a valuation that many analysts consider fair relative to its historical averages and peer group in the FTSE 100. Recent trading volume has remained consistent, with over 3 million shares changing hands daily, reflecting healthy liquidity for institutional and retail investors alike.
2026 Revenue and Profit Guidance
GSK has officially reaffirmed its financial targets for 2026, expecting a “key year of execution.” The company anticipates turnover growth between 3% and 5% at constant exchange rates, driven largely by its Specialty Medicines division.
Core operating profit is projected to rise by 7% to 9%, outpacing revenue growth due to improved product mix and operational efficiencies. Management expects these margins to be supported by lower legal expenses compared to previous years and a continued focus on R&D productivity in oncology and infectious diseases.
Dividend Yield and Payment Schedule
For income-focused investors, GSK remains a prominent choice with a prospective dividend yield of approximately 3.4% to 3.6%. The company has declared an expected total dividend of 70p per share for 2026, up from 66p in 2025.
The provisional 2026 dividend timetable includes key dates for the first half of the year. The Q1 2026 dividend is scheduled for an ex-dividend date of May 14, 2026, with a payment date of July 9, 2026. Subsequent payments are expected in October 2026 and January 2027, maintaining the company’s quarterly distribution policy.
Specialty Medicines and HIV Growth
The Specialty Medicines segment, which includes high-margin treatments for Respiratory, Immunology, and Oncology, grew by 17% in the previous fiscal year. This momentum is expected to carry through 2026 as newer products gain wider market access in the US and Europe.
In the HIV sector, GSK’s subsidiary ViiV Healthcare continues to dominate with long-acting injectable treatments like Cabenuva. Recent data released in early 2026 demonstrates superior efficacy for these long-acting options over daily oral pills, providing a defensive moat against generic competition.
Oncology Pipeline Breakthroughs
GSK’s oncology portfolio saw a 43% sales increase recently, fueled by demand for Blenrep and Jemperli. The company has over 29 projects in clinical development for cancer, focusing on “first-in-class” assets that address unmet needs in multiple myeloma and endometrial cancer.
Vaccines Division Performance
The vaccines business remains a cornerstone of GSK’s strategy, led by the shingles vaccine Shingrix and the RSV vaccine Arexvy. While US market penetration is high, GSK is seeing significant growth in international markets, particularly in China and Japan, where expanded age indications were approved in early 2026.
Major 2026 Clinical Trial Readouts
The 2026 calendar is packed with “pivotal” readouts that could significantly impact the GSK share price. Investors are specifically watching for data on bepirovirsen, a potential functional cure for chronic hepatitis B, which is currently under regulatory review in the EU and Japan.
Other critical updates expected this year include phase III results for camlipixant (chronic cough) and depemokimab for severe asthma. Positive data from these trials would clear the path for blockbuster status and support the company’s long-term sales outlook toward 2031.
Strategic Acquisitions and M&A
In March 2026, GSK completed the acquisition of RAPT Therapeutics, a move designed to strengthen its immunology pipeline. The $1.7 billion deal brings in oral small molecules that target inflammation, complementing GSK’s existing biologic therapies.
This acquisition follows a trend of “bolt-on” deals where GSK buys smaller biotech firms with late-stage assets. By avoiding massive, dilutive mergers, the company aims to maintain a healthy balance sheet while ensuring a steady stream of new product launches.
Technical Analysis of GSK Stock
From a technical perspective, the GSK share price has found strong support near the 2,000 GBX level. Traders often look at the 200-day moving average as a key indicator of long-term trend health, and as of March 2026, the stock is trading comfortably above this line.
Relative Strength Index (RSI) levels indicate that the stock is currently in neutral territory, neither overbought nor oversold. A break above the resistance level at 2,150 GBX could signal a move toward the 52-week highs, especially if Q1 2026 results exceed analyst expectations.
Risks and Market Challenges
While the outlook is positive, GSK faces ongoing risks from drug pricing legislation in the United States. The Inflation Reduction Act (IRA) remains a point of concern for pharmaceutical firms, as it allows for government price negotiations on certain high-spend drugs.
Additionally, patent expirations for older products require GSK to constantly innovate. The company must successfully transition patients from older oral therapies to newer, long-acting biologics to prevent revenue erosion from generic manufacturers.
Environmental and Social Governance (ESG)
GSK currently ranks at the top of the Access to Medicine Index, a reflection of its efforts to provide vaccines and treatments to developing nations. For ESG-conscious investors, this leadership position reduces the risk of reputational damage and regulatory backlash.
The company has also committed to net-zero carbon emissions across its operations by 2030. In 2026, GSK launched a “low carbon” version of its Ventolin inhaler, which significantly reduces the environmental footprint of one of its most widely used products.
Practical Information for Investors
Exchange Listings
GSK is primarily listed on the London Stock Exchange (LSE) under the ticker symbol GSK. It is also available as American Depositary Shares (ADS) on the New York Stock Exchange (NYSE), where each ADS represents two ordinary shares.
Trading Hours
Investors can trade GSK on the LSE from 8:00 AM to 4:30 PM GMT, Monday through Friday. For those trading on the NYSE, market hours are 9:30 AM to 4:00 PM EST.
How to Buy GSK Shares
- Brokerage Account: You will need a trading account that provides access to UK stocks (LSE) or US-listed ADS.
- Research: Use official company announcements from the GSK Investor Relations portal for the most accurate data.
- Dividends: Ensure your broker supports Dividend Reinvestment Plans (DRIP) if you wish to automatically buy more shares with your payouts.
Key 2026 Strategic Pillars
- Pipeline Execution: 2026 is a “year of delivery” with pivotal data readouts for bepirovirsen (Hepatitis B) and camlipixant (Chronic Cough) expected to act as major stock catalysts.
- Financial Discipline: Reaffirmed 2026 guidance targets core EPS growth of 7% to 9%, supported by a returns-based approach to marketing and R&D spending.
- Shareholder Value: An expected total dividend of 70p for 2026, combined with the ongoing execution of its £2 billion share buyback program, underscores a strong commitment to returning capital.
- M&A Focus: Following the $2.2 billion RAPT Therapeutics acquisition, GSK continues to eye “bolt-on” deals in the £2bn–£4bn range to bolster its late-stage oncology and immunology assets.
Frequently Asked Questions
How does GSK’s 2026 dividend compare to 2025?
The projected 2026 dividend of 70p per share represents a 6.1% increase over the 66p paid in 2025, reflecting the company’s improved cash flow and earnings growth.
What are the biggest risks to the GSK share price in 2026?
The primary risks include potential negative clinical trial results for late-stage assets, currency fluctuations (specifically USD/GBP), and evolving healthcare policies in the US regarding vaccine mandates and drug price negotiations.
Who is the current CEO of GSK?
Luke Miels took over as CEO in January 2026, succeeding Emma Walmsley. Miels previously served as the company’s Chief Commercial Officer and has emphasized a strategy of “sharper, faster” drug development.
What is the analyst consensus for GSK stock in 2026?
The consensus is generally a “Hold” to “Moderate Buy,” with an average 12-month price target near 1,966 GBX, though recent bullish reports have set high-end targets as high as 2,300 GBX.
Final Thoughts
GSK plc stands as a revitalized leader in the global biopharma sector, successfully navigating the transition under its new CEO, Luke Miels. The company’s trajectory is defined by a rigorous shift toward high-margin Specialty Medicines and a world-class Vaccines portfolio, which together have cushioned the impact of maturing products in the General Medicines category.
With the share price holding steady around the 2,076 GBX mark, investor sentiment remains cautiously optimistic. The firm’s ability to maintain its 2031 sales target of £40 billion+ suggests a high level of confidence in its internal R&D engine. While broader market risks—such as US drug pricing reforms and ongoing patent litigation—persist, GSK’s disciplined capital allocation and growing dividend yield provide a compelling case for both value and income-focused investors.
To Read More: Manchester Independent